Please assess the completion status of the following clinical trial:

Trial Title: Safety of Buprenorphine Transdermal System (BTDS) in Subjects With Acute Postoperative Pain After Total Knee Replacement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females of 18 to 80 years of age with American Society of Anesthesiologists (ASA) physical status classification of 1, 2 or 3~* Scheduled to undergo unilateral total knee arthroplasty (TKA) for the treatment of the osteoarthritis.~Exclusion Criteria:~* Subjects who have pain or disability in a site other than the operative joint.~* Subjects who have had total knee arthroplasty within 6 months of the scheduled surgery or are scheduled to undergo bilateral knee arthroplasty.~* Subjects whose body mass index (BMI) is 40 or more.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- BTDS 10 (Type: EXPERIMENTAL): Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear
- BTDS 20 (Type: EXPERIMENTAL): Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
- BTDS 30 (Type: EXPERIMENTAL): Buprenorphine transdermal patch 30 mcg/h applied for 7-day wear
- Placebo TDS (Type: PLACEBO_COMPARATOR): Placebo patches were similar to BTDS 10 and 20.

Based on this trial design, predict the completion outcome and termination type (if applicable).